自閉症スペクトラム治療市場の2030年までの予測- 薬物療法別、疾患別、年齢層別、流通チャネル別、地域別の世界分析

Stratistics MRCによると、世界の自閉症スペクトラム治療市場は2023年に21億米ドルを占め、予測期間中にCAGR 9.9％で成長し、2030年には43億米ドルに達すると予測されています。

自閉症スペクトラム障害（ASD）は、脳の変化によって引き起こされる発達障害として知られています。自閉スペクトラム症（ASD）患者には、遺伝的疾患のような区別が認められている人もいます。それ以外の原因はまだわかっていません。科学者によれば、人が発達する最も典型的な方法は、自閉症スペクトラム障害（ASD）に寄与する多くの理由によって変化すると考えられています。アスペルガー症候群、自閉性障害、広汎性発達障害（PDD）はすべて自閉症スペクトラム（ASD）のカテゴリーに含まれます。

米国医師会（AMA）によると、米国の医療支出は2020年に9.7%増加し、4兆1,000億米ドル、国民一人当たり1万2,530米ドルに達します。

市場力学：

促進要因

• 自閉症スペクトラムの世界的増加。
• ASD診断の有病率の上昇により、効果的な介入、治療、支援システムに対する需要が高まっています。このため、行動療法から医薬品による介入まで、幅広い治療法の開発に向けた調査、技術革新、投資が活発化しています。社会がASDをより認識し、ASD患者の生活の質の向上を求めるようになるにつれ、多様で包括的な治療オプションの市場は拡大し、ASD患者の進化するニーズに応えるため、進歩、専門化、オーダーメイドのアプローチの機会を提供しています。

抑制要因

• 治療と診断にかかる費用の高さ。
• 治療、介入、投薬、診断にかかる費用は、多くの家族やヘルスケアシステムにとって法外なものです。この経済的負担は、しばしば包括的なケアへのアクセスを制限し、その結果、治療の可用性と質に不公平をもたらします。その結果、ASD患者がタイムリーで効果的な介入を受けられるようにするためには、経済的な障壁に対処することが不可欠となります。コストを削減し、保険適用を拡大し、利用しやすいサポートシステムを促進する努力は、この障害を克服し、ASD患者により良い結果をもたらすために不可欠です。

機会

• ASDに関する認識の高まりと投資の増加。
• ASDに対する一般市民の理解が深まったことで、アクセスしやすく効果的な介入方法に対する需要が高まり、治療方法の研究と革新が促進されています。この認識はまた、治療法、薬物療法、支援技術の進歩を促進し、官民両セクターからの投資の増加を引き寄せています。資金プールが拡大することで、ASD患者のユニークなニーズに対応する、カスタマイズされたエビデンスに基づいたソリューションの開発が可能になります。このような認識と投資の相乗効果により、ASDの影響を受けた人々の治療結果の改善と生活の質の向上への道が開かれます。

脅威

• 製品承認に関する厳しい規制。
• 治療、投薬、介入に対する複雑で長い承認プロセスは、革新的な治療法の利用を遅らせ、ASD患者のタイムリーなアクセスを妨げています。これらの規制は、患者の安全のために必要ではあるが、関連する時間やコストの制約により、この分野への投資や研究を妨げる可能性があります。有望な治療が規制状況を効率的かつ効果的に通過し、遅れを最小限に抑え、患者の転帰を最適化するためには、厳格な基準とASD患者の進化するニーズへの緊急性のバランスをとることが不可欠です。

COVID-19の影響：

• COVID-19の流行は自閉症スペクトラム障害（ASD）治療市場に大きな影響を与えました。ヘルスケアサービス、セラピーセッション、学校閉鎖の混乱は、ASD患者の通常のサポートシステムを崩壊させました。遠隔医療と遠隔介入が注目を集めたが、対面治療は課題に直面しました。サプライチェーンの混乱は薬の入手に影響を与えました。パンデミックは、弾力的で適応性のある治療アプローチの必要性を浮き彫りにしました。社会が回復するにつれ、遠隔医療ソリューションの進歩とともに、利用しやすく柔軟性のある介入に再び焦点が当てられるようになり、自閉症患者への継続的かつ効果的な支援を確保するための混合的アプローチが強調され、ASD治療の将来が形作られるかもしれないです。
• 抗精神病薬セグメントは予測期間中最大となる見込み
• 抗精神病薬は自閉症スペクトラム治療市場で大きなシェアを占めています。抗精神病薬はASD治療薬として特別に承認されているわけではないが、攻撃性、過敏性、反復行動などの行動症状を管理するために適応外で処方されることがあります。しかし、副作用の可能性や長期的な効果に関する限られたエビデンスのため、その使用には懸念があります。現在進行中の調査は、ASDの状況における有効性と安全性をよりよく理解することを目的としており、課題行動への対処とこれらの薬剤に関連するリスクの最小化との間のバランスを取ることを追求し、それによりASD患者のより包括的で十分な情報に基づいた治療状況に貢献することを目指しています。
• 病院薬局セグメントは予測期間中最も高いCAGRが見込まれる
• 予測期間中、自閉症スペクトラム治療市場で最もCAGRが高いのは病院薬局です。必要不可欠な薬剤、治療、介入へのアクセスを提供します。これらの薬局は、抗精神病薬、抗うつ薬、ASD患者の多様なニーズに対応するその他の治療法などの処方薬を調剤します。また、適切な薬剤管理、投与量、投与方法を確保するとともに、介護者やヘルスケア専門家への指導やサポートも行っています。病院薬局は、治療計画を最適化し、医療チーム間の連携を促進し、ASD患者が管理・監督された環境で必要な治療を受けられるようにすることで、転帰とケアの質の向上に貢献しています。

最大のシェアを占める地域

北米は重要な位置を占めており、予測期間中最大のシェアを占めると予想されています。この地域は先進的なヘルスケアインフラ、調査能力、意識の高まりがあり、製薬業界や研究機関が確立されているため、ASD治療におけるイノベーションが促進されます。強固な保険適用とヘルスケアへのアクセスは、ASD患者の治療へのアクセス向上に貢献しています。さらに、北米の医療専門家、研究者、支援団体間の協力的なアプローチは、エビデンスに基づいた介入やオーダーメイドの治療計画の開発をサポートしています。これらの要因から、北米はASD治療の展望を形成する重要なプレーヤーとして、治療結果の改善と患者の幸福に焦点を当てています。

CAGRが最も高い地域

アジア太平洋地域は、人口が多く多様性に富んでいること、認知度が高まっていること、ヘルスケアインフラが成長していることが要因となって、自閉症スペクトラム治療市場において最も高いCAGRで成長しました。この地域ではASD患者の有病率が上昇しているため、効果的な介入に対する需要が高まっており、研究、イノベーション、治療アプローチへの投資の機会が創出されています。遠隔医療やデジタルプラットフォームへのアクセスは拡大しており、遠隔サポートや治療の提供に役立っています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下のいずれかの無料カスタマイズオプションをご提供いたします：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• エグゼクティブサマリー
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 一次調査情報源
  • 二次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の自閉症スペクトラム治療市場：薬物療法別

• 抗精神病薬
• 抗うつ薬
• 刺激薬
• 睡眠薬
• その他の薬物療法

第6章 世界の自閉症スペクトラム治療市場：疾患別

• 自閉性障害
• アスペルガー症候群
• 広汎性発達障害（PDD）
• その他の疾患

第7章 世界の自閉症スペクトラム治療市場：年齢層別

• 小児
• 成人

第8章 世界の自閉症スペクトラム治療市場：流通チャネル別

• 病院薬局
• ドラッグストア・小売薬局
• オンライン薬局

第9章 世界の自閉症スペクトラム治療市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、提携、合弁事業
• 買収と合併
• 新製品の上市
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Curemark, LLC
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Alembic Pharmaceuticals Limited
• Aurobindo Pharma Ltd.
• Merck & Co., Inc.
• Axial Therapeutics Inc.
• Novartis AG.
• F. Hoffmann-La Roche Ltd
• Otsuka Pharmaceutical Co., Ltd.
• PaxMedica
• Janssen Pharmaceuticals, Inc.
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Q BioMed Inc.
• Stalicla
• Teva Pharmaceutical Industries Ltd.
• Yamo Pharmaceuticals
• Zynerba Pharmaceuticals, Inc

List of Tables

• Table 1 Global Autism Spectrum Disorder Treatment Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
• Table 3 Global Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
• Table 4 Global Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
• Table 5 Global Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
• Table 6 Global Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
• Table 7 Global Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
• Table 8 Global Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
• Table 9 Global Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
• Table 10 Global Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
• Table 11 Global Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
• Table 12 Global Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
• Table 13 Global Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
• Table 14 Global Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
• Table 15 Global Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
• Table 16 Global Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 17 Global Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 18 Global Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
• Table 19 Global Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 20 North America Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 21 North America Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
• Table 22 North America Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
• Table 23 North America Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
• Table 24 North America Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
• Table 25 North America Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
• Table 26 North America Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
• Table 27 North America Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
• Table 28 North America Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
• Table 29 North America Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
• Table 30 North America Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
• Table 31 North America Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
• Table 32 North America Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
• Table 33 North America Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
• Table 34 North America Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
• Table 35 North America Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 36 North America Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 37 North America Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
• Table 38 North America Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 39 Europe Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 40 Europe Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
• Table 41 Europe Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
• Table 42 Europe Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
• Table 43 Europe Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
• Table 44 Europe Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
• Table 45 Europe Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
• Table 46 Europe Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
• Table 47 Europe Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
• Table 48 Europe Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
• Table 49 Europe Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
• Table 50 Europe Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
• Table 51 Europe Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
• Table 52 Europe Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
• Table 53 Europe Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
• Table 54 Europe Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 55 Europe Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 56 Europe Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
• Table 57 Europe Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 58 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 59 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
• Table 60 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
• Table 61 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
• Table 62 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
• Table 63 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
• Table 64 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
• Table 65 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
• Table 66 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
• Table 67 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
• Table 68 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
• Table 69 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
• Table 70 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
• Table 71 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
• Table 72 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
• Table 73 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 74 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 75 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
• Table 76 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 77 South America Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 78 South America Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
• Table 79 South America Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
• Table 80 South America Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
• Table 81 South America Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
• Table 82 South America Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
• Table 83 South America Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
• Table 84 South America Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
• Table 85 South America Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
• Table 86 South America Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
• Table 87 South America Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
• Table 88 South America Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
• Table 89 South America Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
• Table 90 South America Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
• Table 91 South America Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
• Table 92 South America Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 93 South America Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 94 South America Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
• Table 95 South America Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 96 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 97 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
• Table 98 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
• Table 99 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
• Table 100 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
• Table 101 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
• Table 102 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
• Table 103 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
• Table 104 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
• Table 105 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
• Table 106 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
• Table 107 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
• Table 108 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
• Table 109 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
• Table 110 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
• Table 111 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 112 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 113 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
• Table 114 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)

According to Stratistics MRC, the Global Autism Spectrum Disorder Treatment Market is accounted for $2.1 billion in 2023 and is expected to reach $4.3 billion by 2030 growing at a CAGR of 9.9% during the forecast period. A developmental condition brought on by variations in the brain is known as autism spectrum disorder (ASD). Some individuals with autism spectrum disorder (ASD) have a recognized distinction, like a genetic illness. Additional causes are still unknown. The most typical ways that people develop are thought to be altered by a number of reasons that contribute to autism spectrum disorder (ASD), according to scientists. Asperger's syndrome, autistic disorder, and pervasive developmental disorder (PDD) are all included in the category of autism spectrum disorder (ASD).

According to American Medical Association (AMA), health spending in the U.S. increased by 9.7% in 2020 to $4.1 trillion or $12,530 per capita.

Market Dynamics:

Driver:

• Global rise in Autism Spectrum Disorder.

• The rising prevalence of ASD diagnoses has created a growing demand for effective interventions, therapies, and support systems. This has fueled research, innovation, and investment in developing a wide range of treatments, from behavioral therapies to pharmaceutical interventions. As societies become more aware of ASD and seek improved quality of life for affected individuals, the market for diverse and comprehensive treatment options expands, offering opportunities for advancement, specialization, and tailored approaches to cater to the evolving needs of those with ASD.

Restraint:

• High cost for treatment and diagnosis.

• The expenses associated with therapies, interventions, medications, and diagnostic procedures can be prohibitive for many families and healthcare systems. This financial burden often limits access to comprehensive care, resulting in inequities in treatment availability and quality. As a consequence, addressing the affordability barrier becomes crucial to ensuring that individuals with ASD receive timely and effective interventions. Efforts to reduce costs, increase insurance coverage, and promote accessible support systems are essential to overcoming this obstacle and ensuring better outcomes for those with ASD.

Opportunity:

• Rising awareness pertaining ASD and growing number of investments.

• Greater public understanding of ASD has led to heightened demand for accessible and effective interventions, encouraging research and innovation in treatment methods. This awareness has also attracted increased investment from both the public and private sectors, driving advancements in therapies, medications, and assistive technologies. The expanding pool of funds allows for the development of tailored and evidence-based solutions that address the unique needs of individuals with ASD. This synergy of awareness and investment paves the way for improved treatment outcomes and enhanced quality of life for those affected by ASD.

Threat:

• Stringent regulations pertaining to product approval.

• The complex and lengthy approval processes for therapies, medications, and interventions can delay the availability of innovative treatments, hindering timely access for individuals with ASD. These regulations, while necessary for patient safety, can deter investment and research in the field due to the associated time and cost constraints. Balancing rigorous standards with the urgency to address the evolving needs of those with ASD is essential to ensuring that promising treatments can navigate the regulatory landscape efficiently and effectively, minimizing delays and optimizing patient outcomes.

COVID-19 Impact:

• The COVID-19 pandemic has significantly impacted the Autism Spectrum Disorder (ASD) treatment market. Disruptions in healthcare services, therapy sessions, and school closures have disrupted the usual support systems for individuals with ASD. Telehealth and remote interventions gained prominence, but in-person therapies faced challenges. Supply chain disruptions affected medication availability. The pandemic highlighted the need for resilient and adaptable treatment approaches. As societies recover, a renewed focus on accessible and flexible interventions, along with advancements in telehealth solutions, may shape the future of ASD treatment, emphasizing a blended approach to ensure continuous and effective support for individuals with autism.

• The antipsychotic drugs segment is expected to be the largest during the forecast period

• The antipsychotic drugs have a significant share in the Autism Spectrum Disorder Treatment market. While not specifically approved for ASD, they are sometimes prescribed off-label to manage behavioral symptoms such as aggression, irritability, and repetitive behaviors. However, their use raises concern due to potential side effects and limited evidence of long-term benefits. Ongoing research aims to better understand their efficacy and safety in the context of ASD, seeking to strike a balance between addressing challenging behaviors and minimizing the risks associated with these medications, thereby contributing to a more comprehensive and informed treatment landscape for individuals with ASD.

• The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

• The hospital pharmacies have the highest CAGR within the Autism Spectrum Disorder Treatment market over the forecast period. Providing access to essential medications, therapies, and interventions. These pharmacies dispense prescribed medications such as antipsychotics, antidepressants, and other therapies that address the diverse needs of individuals with ASD. They ensure proper medication management, dosage, and administration, while also offering guidance and support to caregivers and healthcare professionals. Hospital pharmacies contribute to optimizing treatment plans, facilitating collaboration between medical teams, and ensuring that individuals with ASD receive the necessary treatments within a controlled and supervised environment, thereby contributing to improved outcomes and quality of care.

Region with largest share:

North America holds a significant position and expected to hold a largest share over the forecast period. Due to the advanced healthcare infrastructure, research capabilities, and increasing awareness in the region and the well-established pharmaceutical industry and research institutions drive innovation in ASD interventions. Robust insurance coverage and healthcare accessibility contribute to better treatment access for individuals with ASD. Additionally, North America's collaborative approach among medical professionals, researchers, and advocacy groups supports the development of evidence-based interventions and tailored treatment plans. These factors collectively position North America as a key player in shaping the ASD treatment landscape with a focus on improved outcomes and patient well-being.

Region with highest CAGR:

The Asia Pacific region witnessed highest CAGR in the Autism Spectrum Disorder Treatment market, driven by its large and diverse population, increasing awareness, and growing healthcare infrastructure. The region's rising prevalence of ASD cases has prompted a growing demand for effective interventions, creating opportunities for research, innovation, and investment in treatment approaches. Access to telehealth and digital platforms is expanding, aiding in providing remote support and therapies.

Key players in the market:

Some of the key players in Autism Spectrum Disorder Treatment market include: Curemark, LLC, Eli Lilly and Company, Bristol-Myers Squibb Company, Alembic Pharmaceuticals Limited, Aurobindo Pharma Ltd., Merck & Co., Inc., Axial Therapeutics Inc., Novartis AG., F. Hoffmann-La Roche Ltd, Otsuka Pharmaceutical Co., Ltd., PaxMedica, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Pfizer Inc., Q BioMed Inc., Stalicla, Teva Pharmaceutical Industries Ltd., Yamo Pharmaceuticals and Zynerba Pharmaceuticals, Inc.

Key Developments:

• In December2022, Bened Life released the first gut-brain medical probiotic, Neuralli. Made in the United States and utilizing the patented probiotic strain L. plantarum PS128, Neuralli is designed to promote mental health and support neurological conditions including but not limited to Parkinson's disease (PD) and autism spectrum disorder (ASD).

• In October2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), reported the highly successful completion of the phase 1b trials for its lead drug candidate STP1.

• In February 2022,Axial Therapeutics announced that the company has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for their lead candidate AB-2004, a molecular therapeutic targeting the gut is being studied for the treatment of irritability associated with ASD.

Drug Therapies Covered:

• Antipsychotic Drugs
• Antidepressants
• Stimulants
• Sleep Medications
• Other Drug Therapies

Diseases Covered:

• Autistic Disorder
• Asperger Syndrome
• Pervasive Developmental Disorder (PDD)
• Other Diseases

Age Groups Covered:

• Children
• Adults

Distribution Channels Covered:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Autism Spectrum Disorder Treatment Market, By Drug Therapy

• 5.1 Introduction
• 5.2 Antipsychotic Drugs
• 5.3 Antidepressants
• 5.4 Stimulants
• 5.5 Sleep Medications
• 5.6 Other Drug Therapies

6 Global Autism Spectrum Disorder Treatment Market, By Disease

• 6.1 Introduction
• 6.2 Autistic Disorder
• 6.3 Asperger Syndrome
• 6.4 Pervasive Developmental Disorder (PDD)
• 6.5 Other Diseases

7 Global Autism Spectrum Disorder Treatment Market, By Age Group

• 7.1 Introduction
• 7.2 Children
• 7.3 Adults

8 Global Autism Spectrum Disorder Treatment Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital Pharmacies
• 8.3 Drug Stores & Retail Pharmacies
• 8.4 Online Pharmacies

9 Global Autism Spectrum Disorder Treatment Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Curemark, LLC
• 11.2 Eli Lilly and Company
• 11.3 Bristol-Myers Squibb Company
• 11.4 Alembic Pharmaceuticals Limited
• 11.5 Aurobindo Pharma Ltd.
• 11.6 Merck & Co., Inc.
• 11.7 Axial Therapeutics Inc.
• 11.8 Novartis AG.
• 11.9 F. Hoffmann-La Roche Ltd
• 11.10 Otsuka Pharmaceutical Co., Ltd.
• 11.11 PaxMedica
• 11.12 Janssen Pharmaceuticals, Inc.
• 11.13 Johnson & Johnson Services Inc.
• 11.14 Pfizer Inc.
• 11.15 Q BioMed Inc.
• 11.16 Stalicla
• 11.17 Teva Pharmaceutical Industries Ltd.
• 11.18 Yamo Pharmaceuticals
• 11.19 Zynerba Pharmaceuticals, Inc